Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTEST: Phase 1/2 intravenous ATTR-01 in selected epithelial solid tumors
ISRCTN38972074Phase 2Recruiting
- Sponsor
- Accession Therapeutics
- Start
- Feb 2025
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
01
Overview
Phase 2, open-label, single-arm trial of TROCEPT-X in Epithelial neoplasm, pancreatic cancer (PC), bronchial carcinoma and 4 more, sponsored by Accession Therapeutics. Primary endpoints: Safety and tolerability, Objective response rate and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
TROCEPT-X
03
Conditions
Epithelial neoplasmpancreatic cancer (PC)bronchial carcinomabladder cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on ISRCTN38972074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38972074.